BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Securities Report
JB Chemicals and Pharmaceuticals Ltd.’s Q3 FY22 performance was better than our estimates on operational fronts.
Excluding revenue deferred to Q3 FY21 from Q2 FY21, consolidated revenue grew 23% YoY to Rs 6 billion (our estimate: 5.8 billion).
Ebitda margin stood at 21.3%, higher than our estimate of 19.8%. Partially, Q3 also benefited by 50% price increase in Ranitidine. Post the consolidation of Sanzyme portfolio, domestic contribution increased to 55%.
We remain positive on the JB Chemicals’ strategy towards improving productivity in India business, portfolio expansion and cost optimisation.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR